ViaCyte attracts crossover investors for $80M series D

By Sandi Wong | Nov 30, 2018 | 6:28 PM GMT

ViaCyte Inc. (San Diego, Calif.) announced an $80 million tranched series D round to fund development of its Type I diabetes stem cell therapies.

ViaCyte President and CEO Paul